Post by Department of Biotechnology

#DBTMilestones A milestone in India's journey towards advanced healthcare. Supported by the Department of Biotechnology, India's first in-human gene therapy trial for Severe Hemophilia A demonstrated sustained Factor VIII production and achieved a zero bleeding rate following a single treatment, marking a significant step towards precision medicine. The findings were published in the New England Journal of Medicine. As we celebrate 12 years of transformative impact, this milestone reflects DBT's commitment to advancing cutting-edge research that brings innovative therapies closer to patients and strengthens India's leadership in biotechnology. #DBTInnovates #PrecisionMedicine #ViksitBharat2047 Dr Jitendra Singh Rajesh Gokhale BRIC DBT Regional Centre for Biotechnology National Agri-Food Biotechnology Institute (NABI) BRIC-National Institute of Animal Biotechnology (NIAB) Institute for Stem Cell Science and Regenerative Medicine (BRIC-inStem) | Institute of Life Sciences |Institute of Bioresources and Sustainable Development (IBSD) |National Institute of Plant Genome Research (BRIC-NIPGR), India|National Brain Research Centre, Gurgaon |BRIC - Centre for DNA Fingerprinting and Diagnostics (CDFD) |Translational Health Science and Technology Institute (THSTI)|BRIC-National Institute of Immunology|Biotechnology Industry Research Assistance Council (BIRAC)|BRIC-Rajiv Gandhi Centre for Biotechnology|BRIC-National Institute of Biomedical Genomics|Ministry of Earth Sciences|Department of Science & Technology, Government of India|CSIR India|CSIR-NIScPR

Video Content